Competition & Peer Data API & CSV Delivery Connect to AI Assistant via MCP

Niagen Bioscience Inc's Competitiveness

A competitive positioning analysis and financial ratio benchmarking of Niagen Bioscience Inc (NAGE) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.

Peer Data As of Q2 2026
Competitors Tracked
-
Publicly traded peers
Peer Group Market Share
100.00 %
vs 100.00 % a year ago
Revenue Growth Y/Y
-4.28 %
Q2 2026
Net Margin
3.23 %
Q2 2026

Key Findings: Niagen Bioscience Inc vs Its Competitors

  • TTM: Trailing 12-month revenue of 129M vs -M combined for tracked competitors (100.0% combined share).
  • Trending: Latest-quarter revenue run-rate is decelerating (-7.7% annualized vs trailing 12 months).
  • Scale: Niagen Bioscience Inc ranks #8 of 37 companies by market capitalization in the Legal Cannabis industry, holding 2.2% of industry market cap.
  • Peer revenue share: Niagen Bioscience Inc accounted for 100.0% of combined revenue among its tracked peer group, up from 100.0% a year earlier.

Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).

NAGE Sales vs. its Competitors, Q2 2026

Niagen Bioscience Inc generated 100.00 % of the combined sales of its peer group, up from 100.00 % a year earlier.

API endpoints for this dataset
https://api.csimarket.com/api/v1/companies/NAGE/competitors
https://api.csimarket.com/api/v1/companies/NAGE/relationships
https://api.csimarket.com/api/v1/companies/NAGE/similar
Programmatic access for models, analytics, and integration workflows.

For context: the Legal Cannabis industry grew revenue 34.7% year over year, combined, vs -4.3% for Niagen Bioscience Inc. Niagen Bioscience Inc's share of combined industry revenue moved from 1.30% to 0.92%, a loss of 0.38 percentage points.

Niagen Bioscience Inc's Competitor Quality Breadth

Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).

Entity Profitable Expanding Above Industry Growth Distressed
Niagen Bioscience Inc Yes Yes Yes No
Similar-Size Competitors (10) 22% 90% 70% 0%
Similar Growth & Profitability (8) 0.00 % (0 of 8) 75.00 % (6 of 8) 62.50 % (5 of 8) 50.00 % (3 of 6)

Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.

Market Share of the Peer Group, Q2 2026

100%market share
  • Niagen Bioscience Inc100.0%
  • Competitors combined0.0%

Share of combined quarterly revenue of Niagen Bioscience Inc and its 0 tracked competitors.

See Niagen Bioscience Inc's full market share breakdown »

NAGE Stock Performance relative to its Competitors

NAGE Competitors (weighted) Percent change over the selected range

Niagen Bioscience Inc's Share Price Performance vs Peer Groups

Trailing 12-month total share price return, and the share of each group that outperformed the U.S.A. 500 over the same period. Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC.
10%beat U.S.A. 500
Similar-Size
(1 of 10)
0%beat U.S.A. 500
Similar Growth & Profitability
(0 of 3)
Entity TTM Share Price Return
(group: median)
vs U.S.A. 500
Niagen Bioscience Inc -69.40 % Underperformed
Competitors combined (0) 40.4% 63.2%
High-Confidence Competitors (0) 40.4% 63.2%
Similar-Size Competitors (10) 40.4% 63.2%
Similar Growth & Profitability (3) 40.4% 63.2%
Peer Group Share Price Returns

TTM share price return and U.S.A. 500 outperformance for Niagen Bioscience Inc's competitor groups requires a Commercial License.

Source: CSIMarket API (daily market-structure computation). Outperformance is trailing-12-month total return vs the U.S.A. 500 over the same window, not risk-adjusted.

NAGE Stock Performance relative to High-Confidence Competitors

NAGE High-Confidence Competitors (equal-weighted, 2) Percent change over the selected range

NAGE Stock Performance relative to Similar-Size Competitors

NAGE Similar-Size Competitors (equal-weighted, 10) Percent change over the selected range

NAGE Stock Performance relative to Similar Growth & Profitability Competitors

NAGE Similar Growth & Profitability Competitors (equal-weighted, 8) Percent change over the selected range

Niagen Bioscience Inc's Comment on Competition and Industry Peers

The company’s consumer products segment competes directly with other providers of NAD+ boosting dietary supplements and indirectly with suppliers of alternative ingredients offering similar functional characteristics. Some customers serve as authorized resellers of Niagen® consumer products, supporting the direct-to-consumer approach. In the analytical reference standards and services segment, the company operates in a competitive market for standardization and quality testing, facing competition from providers of analytical reference standards and related services, including those developing similar products. Key competitive factors include product quality, technical expertise, customer relationships, product range, pricing, and turnaround times. The pharmaceutical industry is characterized by intense competition, rapid technological advancements, substantial research and development expenditures, and stringent regulatory requirements. Companies developing therapies for rare diseases compete with large pharmaceutical firms, biotechnology companies, academic institutions, and other research organizations with greater resources. Competition is based on scientific and clinical outcomes, safety and efficacy profiles, regulatory approvals, intellectual property rights, and the ability to secure funding and partnerships. Success in this environment is not guaranteed.

Niagen Bioscience Inc's Competitors Named by the Company

Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.
Competitor Basis Confidence Active Sources
BASF Named by the company 85% 2022 to 2026 3
Lonza Group Ltd Named by the company 85% 2022 to 2026 3
US Pharmacopoeia Named by the company 85% 2022 to 2026 3
Glanbia plc Named by the company 85% 2022 to 2026 3
Royal DSM Named by the company 85% 2022 to 2026 3
Elysium Health Named by the company 85% 2022 to 2026 3
MilliporeSigma Named by the company 85% 2022 to 2026 3
LGC Standards Ltd. Named by the company 85% 2022 to 2026 3
Sabinsa Corporation Named by the company 85% 2022 to 2026 3
Extrasynthese Named by the company 85% 2022 to 2026 3
Phytolab Named by the company 85% 2022 to 2026 3
Competitor Evidence Detail

Filing basis, confidence, active dates and source counts for Niagen Bioscience Inc's named competitors require a Commercial License.

Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.

Niagen Bioscience Inc's Business Segment Mix vs Peers

Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).
Company Largest Segment 2nd Segment 3rd Segment
Niagen Bioscience Inc Tru Niagen Consumer Product 81.12 % NIAGEN Related 81.12 % Food Grade Niagen 16.55 %

Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).

Get the full CSIMarket dataset: Subscribe API License